LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. John Kastelein explains the most important points from FOURIER and SPIRE 1&2. He argues that there can no longer be any doubt that lowering LDL is crucial for CVD prevention.

Video navigation menu

What are the practical consequences of these trials? 00:22
How do these data match with other trials? 01:52
What are the most important points from these trials? 02:55
Translation to the clinic 03:36
Which patients should these new drugs be applied to? 04:27
What will the future bring? 04:58

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. John J.P. Kastelein is Professor of Medicine and chairman of the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease

Funding

Funding was provided by an unrestricted educational grant from Amgen

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.